NCT00387647View on ClinicalTrials.gov

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2013

Study Completion Date

August 31, 2014

Conditions
Leukemia
Interventions
DRUG

Azacitidine

Azacitidine given subcutaneously as outlined in treatment arm.

Trial Locations (2)

27710

Duke University Medical Center, Durham

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER